Vaccine News and Research

Latest Vaccine News and Research

New data on Soliris for PNH treatment to be presented at ASH Annual Meeting

Alexion Pharmaceuticals, Inc. today announced that researchers are scheduled to present new data relating to Soliris (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 52nd Annual Meeting of the American Society of Hematology (ASH), to be held December 4 - 7, 2010 at the Orange County Convention Center in Orlando.

9 Nov 2010

New Yorker examines global TB diagnostic challenges

The New Yorker examines the challenges associated with treating tuberculosis across the world and looks at whether a rapid diagnostic test could prevent millions of deaths from the disease.

8 Nov 2010

First Edition: November 8, 2010

Today's health policy headlines include more post-mortem reports about the health law's impact on the election.

8 Nov 2010

Research on immune system may help develop improved vaccines for cancer

Researchers at the University of Cambridge hope to revolutionise cancer therapy after discovering one of the reasons why many previous attempts to harness the immune system to treat cancerous tumours have failed.

8 Nov 2010

New findings could help scientists devise optimal therapies for Friedreich's ataxia

Scripps Research Institute scientists have taken a step closer to understanding the cause of Friedreich's ataxia, a debilitating neurological condition that affects tens of thousands of people worldwide, and so far has no cure.

8 Nov 2010

Scientists identify genes that enable some immune systems to halt HIV; finding could spur drug, vaccine development

Tiny variants in a protein that alerts the body to infection could explain how one in 300 HIV-infected people are able to resist the onset of AIDS for years without needing any treatment, researchers said Thursday in a study published online in the journal Science, Agence France-Presse reports

8 Nov 2010

GeoVax receives $244,500 grant under QTDP program for HIV/AIDS vaccine development

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical firm dedicated to developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that it has been awarded a grant of $244,500 related to its HIV/AIDS vaccine development activities under the Qualifying Therapeutic Discovery Project program.

8 Nov 2010

Inviragen to present data on CHIKV vaccine at ASTMH meeting

Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, together with investigators at the University of Texas Medical Branch (UTMB) and the Division of Vector Borne Diseases (DVBD) of the Centers for Disease Control and Prevention, will make an oral presentation today at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on preclinical results of the Company's experimental chikungunya virus (CHIKV) vaccine.

8 Nov 2010

Researchers take first step towards understanding of rare skin cancer

Leeds-based scientists, funded by Yorkshire Cancer Research headquartered in Harrogate, North Yorkshire, plan to introduce the genetic material of a virus into normal human skin cells to produce skin cells that have features of Merkel Cell Carcinoma cancers.

8 Nov 2010

Sanofi Pasteur's dengue vaccine enters phase III trial in Australia

Sanofi Pasteur, the vaccines division of the pharmaceutical group Sanofi-Aventis, on Thursday announced the company had begun testing its dengue fever vaccine in a Phase III clinical trial in Australia, Dow Jones/Wall Street Journal reports.

8 Nov 2010

Research Roundup: Basing insurance on results, not cost; Americans skeptical of public health efforts; seniors' comprehensive care

Copayment Reductions Generate Greater Medication Adherence In Targeted Patients. As health care costs have increased, some patients have sought to save money by cutting down on their medications.

8 Nov 2010

Antigenics awarded $424,720 grant under QTDP program

Antigenics Inc. today announced that it has been awarded $424,720 in grants under the IRS' Qualifying Therapeutic Discovery Project (QTDP) program. The grants were awarded in recognition of our two qualifying programs: AG-707, a phase 1 therapeutic vaccine for the treatment of genital herpes and QS-21 Stimulon® adjuvant.

4 Nov 2010

HPV vaccine enjoys wide support from medical and public health communities

The vaccine that protects against the potentially cancer-causing human papillomavirus (HPV) enjoys wide support in the medical and public health communities. Yet state laws to require young girls to be vaccinated as a requirement for middle school attendance have aroused controversy with parents, politicians, and even medical and public health experts disagreeing about whether such laws are appropriate.

4 Nov 2010

World's most clinically advanced dengue vaccine candidate enters first phase 3 clinical study

Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur's dengue vaccine, the world's most clinically advanced dengue vaccine candidate, entered its first phase 3 clinical study in Australia.

4 Nov 2010

FIP Annual Meeting to improve global health through advances in pharmaceutical sciences

Global health crises like the recent cholera outbreak in Haiti emphasize the need for new ways to prevent deadly diseases from becoming widespread in developing countries. International experts and scientists will present research ranging from developing a freeze-dried cholera vaccine to new methods of delivering medicines to underserved populations at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in New Orleans, La., Nov. 13-18.

4 Nov 2010

Combination of DC-CIK and stem cell therapy effective to prevent cancer recurrence after surgery

"For brain cancer patients after surgery, the combined DC-CIK and stem cell therapy from Cellonis Biotechnologies can be a very effective method in preventing cancer recurrence," says renowned cancer doctor Dr. Dinggang Li.

4 Nov 2010

Lentigen awarded $1.23M grant under Patient Protection and Affordable Care Act

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that it will receive $1,235,306 in cash grants from the U.S. Government under the Patient Protection and Affordable Care Act.

4 Nov 2010

Afinitor tablets decrease size of SEGA associated with tuberous sclerosis

The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS).

4 Nov 2010

Aduro receives $442,000 grant under QTDP program to support Listeria-based immunotherapy platform

Aduro BioTech announced today that it has been awarded two cash grants totaling approximately $442,000 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

PharmAthene closes public offering of common stock

PharmAthene, Inc. a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it has closed its previously announced registered public offering of 4,300,000 shares of its common stock at a price to the public of $3.50 per share.

4 Nov 2010